[1] 冉晨曦, 何人可, 汤小玲, 等.肿瘤放射治疗中辐射增敏剂的应用进展[J].山东医药, 2015, 55(3):86-88.
Ran CX, He RK, Tang XL, et al. Application progress of radiosensitizer in tumor radiotherapy[J]. Shangdong Med J, 2015, 55(3):86-88.
[2] Tubiana M. The role of local treatment in the cure of cancer[J]. Eur J Cancer, 1992, 28A(12):2061-2069. DOI:10.1016/0959-8049(92)90256-2.
[3] 张叔人.放疗联合免疫治疗肿瘤是今后重要的研究领域[J].实用肿瘤杂志, 2015, 30(6):491-495. DOI:10.13267/j.cnki.syzlzz.2015.06.023.
Zhang SR. Radiotherapy combined with immunotherapy for tumor will be an important research field[J]. J Pract Oncol, 2015, 30(6):491-495.  doi: 10.13267/j.cnki.syzlzz.2015.06.023
[4]

高黎, 徐国镇.鼻咽癌[M].北京:北京大学医学出版社, 2007:49.

Gao L, Xu GZ. Nasopharyngeal carcinoma[M]. Beijing:Peking University Medical Press, 2007:49.
[5] 黄少祥, 樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志, 2013, 37(3):150-152. DOI:10.3760/cma.j.issn.1673-4114.2013.03.006.
Huang SX, Fan TQ. Radiosensitization on non-small cell lung cancer induced by celecoxib[J]. Inter J Radiat Med Nucl Med, 2013, 37(3):150-152.  doi: 10.3760/cma.j.issn.1673-4114.2013.03.006
[6] 陈晓艳, 张江虹, 邵春林. STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志, 2016, 40(3):191-195. DOI:10. 3760/cma.j.issn.1673-4114.2016.03.007.
Chen XY, Zhang JH, Shao CL. Research progresses of correlation between STAT3 and radiosensitivity[J]. Inter J Radiat Med Nucl Med, 2016, 40(3):191-195.  doi: 10.3760/cma.j.issn.1673-4114.2016.03.007
[7]

郑秀龙, 金一尊, 沈瑜.肿瘤治疗增敏药[M].上海:上海科学技术文献出版社, 2002:12-14.

Zheng XL, Jin YZ, Shen Y. Tumor therapy sensitizers[M]. Shanghai:Shanghai Science and Technical Literature Press, 2002:12-14.
[8] Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy[J]. Radiology, 1972, 105(1):135-142. DOI:10.1148/105.1.135.
[9] Oronsky B, Scicinski J, Ning S, et al. Rockets, radiosensitizers, and RRx-001:an origin story part Ⅰ[J]. Discov Med, 2016, 21(115):173-180.
[10] Mercer WE. Checking on the cell cycle[J]. J Cell Biochem Suppl, 1998(S30-31):50-54. DOI:10.1002/(SICI)1097-4644(1998)72:30/31+3.3.CO; 2-#?.
[11] Watanabe T, Ichikawa A, Saito H, et al. Overexpression of the MDM2 oncogene in leukemia and lymphoma[J]. Leuk Lymphoma, 1996, 21(5/6):391-397.DOI:10.3109/10428199609093436.
[12] Vitturi DA, Sun CW, Harper VM, et al. Antioxidant functions for the hemoglobin β93 cysteine residue in erythrocytes and in the vascular compartment in vivo[J]. Free Radic Biol Med, 2013, 55(1):119-129. DOI:10.1016/j.freeradbiomed.2012.11.003.
[13] Scicinski J, Oronsky B, Ning S, et al. NO to cancer:The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001[J]. Redox Biol, 2015, 6(4):1-8. DOI:10.1016/j.redox.2015.07.002.
[14]

Fens MH, Larkin SK, Oronsky B, et al. The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions[J/OL]. PLoS One, 2014, 9(7):e101626[2017-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090171/pdf/pone.0101626.pdf.DOI:10.1371/journal.pone.0101626.
[15] Grubina R, Huang Z, Shiva S, et al. Concerted nitric oxide formationand release from the simultaneous reactions of nitrite with deoxy-and oxyhemoglobin[J]. J Biol Chem, 2007, 282(17):12916-12927. DOI:10.1074/jbc.M700546200.
[16] Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation[J]. Nat Med, 2003, 9(12):1498-1505. DOI:10.1038/nm954.
[17]

Straessler NA, Cannizzo LF, Li P, et al. Methods of synthesizing and isolating N-(bromoacetyl)-3, 3-dinitroazetidine and a composition including the same:US, WO 2011/100090A1[P]. 2011-08-18.
[18] Ning S, Bednarski M, Oronsky B, et al. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials[J]. Cancer Res, 2012, 72(10):2600-2608. DOI:10.1158/0008-5472.CAN-11-2303.
[19] Ning S, Tian J, Marshall DJ, et al. Anti-alphav integrin monoclo-nal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats[J]. Cancer Res, 2010, 70(19):7591-7599. DOI:10.1158/0008-5472. CAN-10-1639.
[20] Scicinski J, Oronsky B, Cooper V, et al. Development of methods for the bioanalysis of RRx-001 and metabolites[J]. Bioanalysis, 2014, 6(7):947-956. DOI:10.4155/bio.13.331.
[21] Reid T, Oronsky B, Scicinski J, et al. Safety and activity of RRx-001 in patients with advanced cancer:a first-in-human, open-label, dose-escalation phase 1 study[J]. Lancet Oncol, 2015, 16(9):1133-1142. DOI:10.1016/S1470-2045(15)00089-3.
[22] Oronsky B, Paulmurugan R, Foygel K, et al. RRx-001:a systemi-cally non-toxic M2-to-M1 macrophage stimulating and prosensiti-zing agent in Phase Ⅱ clinical trials[J]. Expert Opin Investig Drugs, 2017, 26(1):109-119. DOI:10.1080/13543784.2017.1268600.
[23] Kim MM, Parmar H, Cao Y, et al. Whole brain radiotherapy and RRx-001:two partial responses in radioresistant melanoma brain metastases from a phase Ⅰ/Ⅱ clinical trial:a TITE-CRM phase Ⅰ/Ⅱ clinical trial[J]. Transl Oncol, 2016, 9(2):108-113. DOI:10.1016/j.tranon.2015.12.003.
[24] Yalcin O, Oronsky B, Carvallho LJ, et al. From METS to malaria:RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria[J]. Malar J, 2015, 14(1):218. DOI:10.1186/s12936-015-0720-5.
[25] Oronsky B, Scicinski J, Reid T, et al. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhi-bits glucose 6-phosphate dehydrogenase in human tumor cells[J]. Discov Med, 2016, 21(116):251-265.
[26] Cabrales P, Oronsky B, Scicinski J. Abstract 1420:RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydroge-nase[J]. Cancer Res, 2014, 74(19 Suppl):1420. DOI:10.1158/1538-7445. AM2014-1420.